SCHEMBL3110244

SCHEMBL3110244

Clc1ccccc1-c1nc(Cl)c2ncccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 7/20 0.47
CYP3A4 P08684 7/20 0.47
CYP2C19 P33261 7/20 0.47
CYP2D6 P10635 6/20 0.47
HSD17B10 Q99714 3/20 0.47
USP2 O75604 3/20 0.47
CLK4 Q9HAZ1 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.47
TP53 P04637 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
CYP2C9 P11712 3/20 0.47
MAPK1 P28482 3/20 0.47
TDP1 Q9NUW8 3/20 0.47
METAP1 P53582 1/20 0.46
ALDH1A1 P00352 5/20 0.45
ATM Q13315 2/20 0.44
MAPT P10636 3/20 0.43
ABCB1 P08183 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17445466 0.80 TOP1 (0.50) CYP1A2CYP3A4CYP2D6CLK4MEN1
SCHEMBL3109055 0.76 CYP1A2 (0.64) CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10
SCHEMBL5555284 0.76 PRKD3 (0.45) L3MBTL1METAP1MAPTTOP1CCR1
SCHEMBL13300153 0.76 CYP1A2 (0.50) CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10
SCHEMBL786521 0.74 METAP1 (0.46) CYP1A2CYP3A4CYP2C19CYP2D6HSD17B10
SCHEMBL24953761 0.74 PRMT5 (0.47) CYP3A4CYP2D6LMNATP53L3MBTL1
SCHEMBL17445465 0.74 NPC1 (0.41) CYP3A4CYP2D6HSD17B10LMNATP53
SCHEMBL29907250 0.73 LMNA (0.43) CYP3A4CYP2D6MEN1KMT2ALMNA
SCHEMBL1992034 0.73 LMNA (0.43) CYP3A4CYP2D6MEN1KMT2ALMNA
SCHEMBL1586221 0.72 CYP19A1 (0.55) CYP1A2CYP3A4CYP2C19CYP2D6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2198867-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors Vertex Pharmaceuticals, Inc. (US) 2010-06-23 EP disclosed
EP-1474147-A1 PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2004-11-10 EP disclosed
US-20030199526-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors VERTEX PHARMACEUTICALS, INCORPORATED 2003-10-23 US disclosed
WO-2003049739-A1 PYRIMIDINE-BASED COMPOUNDS USEFUL AS GSK-3 INHIBITORS VERTEX PHARMACEUTICALS, INC. (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199526-A1 Pyrimidine-based compounds useful as GSK-3 inhibitors GSK3B, GSK3A, GSKIP CYP1A2 2209/4885CYP3A4 2517/4885CYP2C19 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.